Clynav

RSS

Salmon pancreas disease vaccine (recombinant DNA plasmid)

Authorised
This medicine is authorised for use in the European Union.

Overview

Clynav is a veterinary vaccine used to protect Atlantic salmon against pancreas disease caused by salmonid alphavirus subtype 3 (SAV3). Pancreas disease in Atlantic salmon can reduce weight gain, leads to damage of the heart, pancreas and skeletal muscle, and may cause death.

The active substance in Clynav is a DNA plasmid (a small piece of DNA) containing the genetic code for making proteins found in salmon pancreas disease virus (SPDV).

This EPAR was last updated on 25/09/2020

Authorisation details

Product details
Name
Clynav
Agency product number
EMEA/V/C/002390
Active substance
pUK-SPDV-poly2#1 DNA plasmid coding for salmon pancreas disease virus proteins
International non-proprietary name (INN) or common name
Salmon pancreas disease vaccine (recombinant DNA plasmid)
Species
Atlantic salmon
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI10AX
Publication details
Marketing-authorisation holder
Elanco GmbH
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
26/06/2017
Contact address

Heinz-Lohmann-Str 4
27472 Cuxhaven
Germany

Product information

27/03/2020 Clynav - EMEA/V/C/002390 - II/0010

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals for Atlantic salmon

Therapeutic indication

For the active immunisation of Atlantic salmon to reduce impaired daily weight gain, and reduce mortality, and cardiac, pancreatic and skeletal muscle lesions caused by pancreas disease following infection with salmonid alphavirus subtype 3 (SAV3).

Assessment history

How useful was this page?

Add your rating